$1,810,000 of HCA HEALTHCARE INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"HR 2191, Physician Led and Rural Access to Quality Care Act; S 1816, Improving Seniors' Timely Access to Care Act of 2025; S 46, Health Care Affordability Act of 2025; S 2355, Patients Deserve Price Tags Act HR 2191, Physician Led and Rural Access to Quality Care Act; S 1816, Improving Seniors' Timely Access to Care Act of 2025; S 46, Health Care Affordability Act of 2025; S 2355, Patients Deserve Price Tags Act"
You can find more data on corporate lobbying on Quiver Quantitative.
HCA Insider Trading Activity
HCA insiders have traded $HCA stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $HCA stock by insiders over the last 6 months:
- SAMUEL N HAZEN (CEO) has made 0 purchases and 7 sales selling 42,877 shares for an estimated $21,483,274.
- JENNIFER BERRES (SVP & Chief Human Res. Officer) has made 0 purchases and 2 sales selling 8,020 shares for an estimated $4,126,950.
- MICHAEL R MCALEVEY (EVP & Chief Legal & Admin Off.) has made 0 purchases and 2 sales selling 5,586 shares for an estimated $2,747,527.
- CHRISTOPHER F. WYATT (SVP & Controller) sold 4,000 shares for an estimated $2,020,000
- MICHAEL S. CUFFE (EVP and Chief Clinical Officer) sold 1,500 shares for an estimated $747,135
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HCA Hedge Fund Activity
We have seen 610 institutional investors add shares of HCA stock to their portfolio, and 604 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 5,306,304 shares (-77.3%) from their portfolio in Q4 2025, for an estimated $2,477,301,085
- FMR LLC added 1,928,240 shares (+101.2%) to their portfolio in Q4 2025, for an estimated $900,218,126
- BANK OF AMERICA CORP /DE/ removed 1,319,037 shares (-63.6%) from their portfolio in Q4 2025, for an estimated $615,805,613
- PACER ADVISORS, INC. removed 911,096 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $425,354,278
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 649,058 shares (+4545.5%) to their portfolio in Q4 2025, for an estimated $303,019,217
- JPMORGAN CHASE & CO removed 627,849 shares (-21.0%) from their portfolio in Q4 2025, for an estimated $293,117,584
- DIAMOND HILL CAPITAL MANAGEMENT INC removed 618,170 shares (-92.9%) from their portfolio in Q4 2025, for an estimated $288,598,846
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HCA Analyst Ratings
Wall Street analysts have issued reports on $HCA in the last several months. We have seen 12 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 01/28/2026
- Barclays issued a "Overweight" rating on 01/28/2026
- Deutsche Bank issued a "Buy" rating on 01/28/2026
- Truist Securities issued a "Buy" rating on 01/28/2026
- Oppenheimer issued a "Outperform" rating on 01/28/2026
- Morgan Stanley issued a "Underweight" rating on 12/15/2025
- UBS issued a "Buy" rating on 10/27/2025
To track analyst ratings and price targets for HCA, check out Quiver Quantitative's $HCA forecast page.
HCA Price Targets
Multiple analysts have issued price targets for $HCA recently. We have seen 18 analysts offer price targets for $HCA in the last 6 months, with a median target of $550.5.
Here are some recent targets:
- Ryan Langston from TD Cowen set a target price of $561.0 on 03/10/2026
- Ann Hynes from Mizuho set a target price of $585.0 on 02/25/2026
- Andrew Mok from UBS set a target price of $635.0 on 02/23/2026
- Benjamin Rossi from JP Morgan set a target price of $535.0 on 02/20/2026
- David Toung from Argus Research set a target price of $560.0 on 02/06/2026
- Stephen Baxter from Wells Fargo set a target price of $481.0 on 01/30/2026
- Michael Wiederhorn from Oppenheimer set a target price of $540.0 on 01/28/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
